These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 21909130

  • 1. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
    Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB.
    Oncogene; 2012 Apr 12; 31(15):1949-62. PubMed ID: 21909130
    [Abstract] [Full Text] [Related]

  • 2. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
    Jung SH, Hwang HJ, Kang D, Park HA, Lee HC, Jeong D, Lee K, Park HJ, Ko YG, Lee JS.
    Oncogene; 2019 Mar 12; 38(10):1639-1650. PubMed ID: 30337688
    [Abstract] [Full Text] [Related]

  • 3. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.
    Clin Cancer Res; 2012 Jan 15; 18(2):380-91. PubMed ID: 22090358
    [Abstract] [Full Text] [Related]

  • 4. Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.
    Havel JJ, Li Z, Cheng D, Peng J, Fu H.
    Oncogene; 2015 Mar 19; 34(12):1487-98. PubMed ID: 24704832
    [Abstract] [Full Text] [Related]

  • 5. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA.
    Leukemia; 2011 Jul 19; 25(7):1064-79. PubMed ID: 21436840
    [Abstract] [Full Text] [Related]

  • 6. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
    Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T.
    Mol Cell Biol; 2007 Jan 19; 27(2):662-77. PubMed ID: 17060456
    [Abstract] [Full Text] [Related]

  • 7. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
    Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, Wendel HG.
    Genes Dev; 2008 Aug 15; 22(16):2178-88. PubMed ID: 18708578
    [Abstract] [Full Text] [Related]

  • 8. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.
    Biosci Rep; 2012 Aug 15; 32(4):413-22. PubMed ID: 22668349
    [Abstract] [Full Text] [Related]

  • 9. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.
    Xu Y, Li N, Xiang R, Sun P.
    Trends Biochem Sci; 2014 Jun 15; 39(6):268-76. PubMed ID: 24818748
    [Abstract] [Full Text] [Related]

  • 10. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
    Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, Longy M, Maki RG, Coindre JM, Antonescu CR.
    Cancer; 2012 Dec 01; 118(23):5878-87. PubMed ID: 22648906
    [Abstract] [Full Text] [Related]

  • 11. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
    Jefferies MT, Cox AC, Shorning BY, Meniel V, Griffiths D, Kynaston HG, Smalley MJ, Clarke AR.
    J Pathol; 2017 Dec 01; 243(4):442-456. PubMed ID: 29134654
    [Abstract] [Full Text] [Related]

  • 12. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
    Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB.
    Cell Signal; 2011 Jan 01; 23(1):201-12. PubMed ID: 20837138
    [Abstract] [Full Text] [Related]

  • 13. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
    Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA.
    Oncotarget; 2014 Jul 15; 5(13):4603-50. PubMed ID: 25051360
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic Roles of the PI3K/AKT/mTOR Axis.
    Aoki M, Fujishita T.
    Curr Top Microbiol Immunol; 2017 Jul 15; 407():153-189. PubMed ID: 28550454
    [Abstract] [Full Text] [Related]

  • 15. Cooperation between p21 and Akt is required for p53-dependent cellular senescence.
    Kim YY, Jee HJ, Um JH, Kim YM, Bae SS, Yun J.
    Aging Cell; 2017 Oct 15; 16(5):1094-1103. PubMed ID: 28691365
    [Abstract] [Full Text] [Related]

  • 16. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.
    Oncol Rep; 2013 Aug 15; 30(2):623-36. PubMed ID: 23728071
    [Abstract] [Full Text] [Related]

  • 17. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
    Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.
    Cell Cycle; 2011 Sep 01; 10(17):3003-15. PubMed ID: 21869603
    [Abstract] [Full Text] [Related]

  • 18. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.
    Adv Enzyme Regul; 2006 Sep 01; 46():249-79. PubMed ID: 16854453
    [Abstract] [Full Text] [Related]

  • 19. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.
    Mitra AK, Jia G, Gangahar DM, Agrawal DK.
    J Cell Mol Med; 2009 Jan 01; 13(1):177-87. PubMed ID: 18363844
    [Abstract] [Full Text] [Related]

  • 20. [Role of MEK/ERK pathway in the regulation of HDACI-induced senescence of transformed rat embryo fibroblasts].
    Kochetkova EIu, Bykova TV, Zubova SG, Pospelova TV.
    Tsitologiia; 2014 Jan 01; 56(8):581-90. PubMed ID: 25697003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.